Antidepressants Show Real Promise Against Chemotherapy-Induced Nerve Pain

Chemotherapy saves lives, but for hundreds of thousands of cancer survivors it leaves behind a painful and often debilitating legacy. Chemotherapy-induced peripheral neuropathy, or CIPN, is a form of nerve damage caused by some of the most widely used anticancer drugs, including platinum compounds, taxanes, bortezomib, thalidomide, and vinca alkaloids. Patients describe burning, tingling, numbness, and sharp shooting pains, usually in the hands and feet, and these symptoms can persist for months or years after treatment ends. A new systematic review published in Pharmacology Research & Perspectives now offers one of the most up-to-date assessments of how antidepressants, a surprising but increasingly central class of pain-modulating drugs, can help these patients.

The scale of the problem is enormous. The review’s authors report that roughly 34 percent of patients worldwide experience CIPN six months or longer after finishing chemotherapy, with prevalence peaking at around 68 percent during the first month after treatment. Symptoms arise because neurotoxic drugs damage the myelin sheaths, axons, and neuronal cell bodies of the dorsal root ganglia, triggering neuroinflammation, elevated pro-inflammatory cytokines, apoptosis, and altered neuronal excitability. Clinicians distinguish positive symptoms, such as allodynia, hyperalgesia, dysesthesia, and paresthesia, from negative symptoms like numbness and motor dysfunction. In severe cases, the condition forces oncologists to reduce chemotherapy doses or abandon potentially curative regimens altogether, making effective symptomatic treatment a genuine clinical priority.

International guidelines from the American Society of Clinical Oncology and the European Society for Medical Oncology currently identify duloxetine, a serotonin-norepinephrine reuptake inhibitor, as the only pharmacological option supported by strong evidence for painful CIPN, though its use remains off-label. The foundational evidence came from a randomized placebo-controlled trial by Smith and colleagues, later confirmed by Hirayama and coworkers in a large open-label Japanese study. Yet clinical practice has moved on, with growing interest in combination and multimodal approaches, and the comparative evidence base had never been systematically consolidated. The new review set out to fill exactly that gap, synthesizing studies published between 2019 and 2025 under contemporary diagnostic and reporting standards.

Methodologically, the review was rigorous and transparent. Two investigators independently searched PubMed, Web of Science, and Scopus following PRISMA guidelines and the PICO framework, with the protocol registered on PROSPERO. From 892 initial records, 374 duplicates were removed, and successive rounds of screening excluded pre-2019 publications, preclinical studies, reviews, editorials, and inaccessible or irrelevant articles. Eleven clinical studies survived the selection process, spanning randomized double-blind placebo-controlled trials, a non-inferiority trial, prospective pilot work, retrospective observational cohorts, and individual case reports. Risk of bias was assessed with the Cochrane RoB 2 tool for randomized trials and the Newcastle-Ottawa Scale for observational studies, and most randomized trials showed low risk across the key domains of randomization, blinding, and outcome measurement.

The patient populations were heterogeneous, reflecting the diversity of oncology practice. Enrolled individuals had breast, gastrointestinal, lung, hematological, head and neck, genitourinary, and other malignancies, with sample sizes ranging from single-patient case reports to more than 230 participants. The antidepressants evaluated included duloxetine at daily doses of 20 to 60 milligrams, oral amitriptyline at 10 to 20 milligrams, topical 10 percent amitriptyline gel, and venlafaxine, alongside combination regimens pairing duloxetine with mirogabalin at 5 to 25 milligrams daily or tapentadol at 50 to 500 milligrams daily. Pain outcomes were tracked with the Numerical Rating Scale, the Visual Analogue Scale, and the Brief Pain Inventory, while neuropathy severity was graded using CTCAE criteria, the Total Neuropathy Score, and the DN4 questionnaire.

The results for duloxetine monotherapy were strikingly consistent. In one double-blind placebo-controlled trial in non-metastatic breast cancer patients receiving paclitaxel, duloxetine cut average pain scores on the Numerical Rating Scale from 4.19 to 2.63 over eight weeks, while CTCAE neuropathy grades fell from 1.48 to 0.79, a statistically significant difference against placebo. A second placebo-controlled trial in gastrointestinal cancer patients treated with oxaliplatin similarly found that duloxetine prevented worsening of peripheral sensory neuropathy, with grade scores improving from 0.86 to 0.62. In a broader randomized trial across multiple tumor types, 44.1 percent of duloxetine-treated patients achieved a clinically significant pain reduction of at least 30 percent, compared with only 18.2 percent on placebo, and 32.4 percent achieved reductions of 50 percent or more versus 3.0 percent of placebo patients. A retrospective observational study was the outlier, reporting only a modest, statistically insignificant Visual Analogue Scale change, likely reflecting uncontrolled dosing and confounding.

Combination therapies generated the most eye-catching numbers, though the authors are careful about interpretation. In a randomized study of 72 breast cancer patients, duloxetine paired with electrostimulation reduced average pain scores from about 6.1 to 3.6 in two weeks. A single case report described mirogabalin plus duloxetine lowering pain scores from 8 to 1 and CTCAE grade from 3 to 1. In a randomized non-inferiority trial of 114 patients, tapentadol combined with duloxetine reduced the Numerical Rating Scale from 7.51 to 2.87, statistically equivalent to tapentadol alone. A prospective randomized comparison of 89 patients found duloxetine outperforming pregabalin on both pain and DN4 neuropathy scores, with duloxetine dropping scores from roughly 7 to 4 over four weeks. Meanwhile, a retrospective cohort in lung cancer showed duloxetine plus low-dose mirogabalin reducing median pain scores from 5.5 to 4.0. Importantly, adverse events remained mild across all regimens, limited mainly to nausea, constipation, dizziness, and transient somnolence, and combination treatments did not increase side-effect burdens relative to monotherapy.

One of the more intriguing findings concerned topical amitriptyline. In a prospective pilot study of 44 patients treated with bortezomib or oxaliplatin, a 10 percent topical amitriptyline emulsion applied twice daily for six months reduced Visual Analogue Scale scores from 7 to 2, with the difference reaching high statistical significance. Topical delivery may offer localized analgesia with far better tolerability than systemic tricyclic therapy, which is otherwise limited by dry mouth, weight gain, and drowsiness. The evidence base remains small, but the result hints at a practical option for patients who cannot tolerate oral agents, and it underscores how routes of administration may reshape the pharmacology of otherwise old drugs.

Why should antidepressants relieve nerve pain at all? The review explains the mechanistic logic. SNRIs like duloxetine and tricyclics like amitriptyline enhance both serotonergic and noradrenergic transmission, strengthening descending inhibitory pathways, particularly noradrenergic projections from the locus coeruleus to the spinal dorsal horn that suppress pain signals before they reach consciousness. Selective serotonin reuptake inhibitors, by contrast, fail to engage these noradrenergic circuits, which may explain their inconsistent efficacy in neuropathic pain. Preclinical work supports these mechanisms, with duloxetine, amitriptyline, and pregabalin all reducing pain behaviors in animal models, although translational gaps persist, especially for pregabalin and venlafaxine, which perform better in the laboratory than in the clinic, likely because animal models incompletely reproduce human CIPN and because dosing and timing differ.

The authors are candid about limitations. Study heterogeneity in design, populations, and outcome measures precluded quantitative meta-analysis, several trials were small, and the restriction to English-language open-access studies published after 2019 may have introduced bias and excluded foundational duloxetine trials, which the authors discussed as context rather than primary evidence. Combination benefits remain hypothesis-generating, since most multimodal studies lacked appropriate comparator arms to disentangle whether effects are additive, synergistic, or driven by a single component. Prevention, too, remains unproven; current evidence supports antidepressants only for treating established CIPN. Still, the message for patients and clinicians is clear and cautiously optimistic: duloxetine stands as the first-line pharmacological option, topical amitriptyline deserves larger trials, and well-designed randomized studies of combination strategies could finally deliver the relief that millions of cancer survivors still lack.

Subject of Research: The efficacy of antidepressants, particularly duloxetine, in managing chemotherapy-induced peripheral neuropathic pain

Article Title: The Role of the Antidepressants in Managing Chemotherapy‐Induced Neuropathic Pain: A Systematic Review

Article References: Caminiti, R., Mazza, V., Nucera, S., Oppedisano, F., Passacatini, L. C., Maiuolo, J., Malafoglia, V., Giorgio, A., Soluri, A., Pileggi, C., Tomino, C., Mollace, V., Ilari, S., & Muscoli, C. (2026). The Role of the Antidepressants in Managing Chemotherapy‐Induced Neuropathic Pain: A Systematic Review. Pharmacology Research & Perspectives, 14(5), Article e70327. https://doi.org/10.1002/prp2.70327

Image Credits: AI Generated

DOI: 10.1002/prp2.70327

Keywords: chemotherapy-induced peripheral neuropathy, CIPN, duloxetine, antidepressants, neuropathic pain, systematic review, SNRI, amitriptyline, cancer survivors, pain management, mirogabalin, tapentadol